PDL BioPharma to Present at the 8th Annual JMP Securities Research Conference on...

PDL BioPharma to Present at the 8th Annual JMP Securities Research Conference
on May 18, 2009

INCLINE VILLAGE, Nev., May 12 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc.
(PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's
president and chief executive officer, will present at the 8th Annual JMP
Securities Research Conference in San Francisco, Calif., on May 18, 2009 at
2:30 p.m. Pacific Time.

To access the live and subsequently archived webcast of the conference call,
go to the company's Web site at http://www.pdl.com and click "Investors."
Please connect to the Web site at least 15 minutes prior to the call to allow
for any software download that may be necessary. A replay will be available at
www.pdl.com starting approximately three hours after completion of the
webcast.

About PDL BioPharma, Inc.
PDL BioPharma pioneered the humanization of monoclonal antibodies and, by
doing so, enabled the discovery of a new generation of targeted treatments for
cancer and immunologic diseases. PDL is focused on maximizing the value of its
antibody humanization patents and related assets. The company receives
royalties on sales of a number of humanized antibody products marketed today
and also may receive royalty payments on additional humanized antibody
products launched before patent expiry in late 2014. For more information,
please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of
PDL BioPharma, Inc.

SOURCE PDL BioPharma, Inc.

Carolyn Wang of WeissComm Partners, +1-415-946-1065, cbwang@wcpglobal.com, for
PDL BioPharma, Inc.